In the quiet desperation of fertility treatment, hope is a powerful currency — and a vulnerable one. A University of Melbourne study has found that most commonly offered IVF add-ons lack meaningful scientific evidence of improving pregnancy outcomes, raising a deeper question about how medicine navigates the space between possibility and proof. When clinics offer unverified treatments to patients already carrying the weight of longing, the line between care and exploitation becomes difficult to see. The challenge now belongs not only to researchers, but to an entire industry asked to choose tr
Most IVF add-ons lack evidence of benefit, Melbourne study finds
Patients experience false hope, financial strain, and unnecessary medical procedures while pursuing fertility treatment.
Clinics offering something signals patients it probably works
Mark
So the study looked at ten add-ons and found only three with any evidence at all. What were those three?
Mimi
EmbryoGlue, endometrial scratching, and physiological intracytoplasmic sperm injection. But even for those, the evidence was weak—not strong.
Luke
How weak is weak? Are we talking "might help" or "probably doesn't hurt"?
Mimi
The source doesn't specify the strength of that weak evidence. We know it's better than the other seven, but the exact magnitude isn't detailed.
Mark
And the other seven—they showed no benefit at all?
Mimi
Either no effect or inconclusive results because the data was limited or low-quality. So it's not always "definitely doesn't work," sometimes it's "we don't have enough good data to know."
Luke
That's an important distinction. Absence of evidence isn't the same as evidence of absence.
Mark
Right. So a patient might reasonably ask: if we don't have good data, why are clinics offering these?
Mimi
That's exactly Lensen's point. Clinics offering something signals to patients that it probably works. But the offering itself isn't based on evidence—it's based on availability and marketing.
Luke
Do we know how much these add-ons cost? That financial strain piece matters.
Mimi
The study doesn't specify costs. We know they add financial burden, but not the actual numbers.
Mark
And the website they built—did it actually change patient behavior?
Mimi
Yes. When they tested it in a large trial, it improved understanding and reduced interest in add-ons without strong evidence.
Luke
That's the most concrete finding in the whole piece—the intervention worked. Everything else is about the problem.
Der Puls
- Of ten common IVF add-ons examined, seven had no credible evidence of improving pregnancy success — yet they remain widely offered and purchased by patients.
- Fertility patients, already emotionally and financially stretched, are interpreting clinic offerings as implicit proof of effectiveness, compounding the harm of unproven treatments.
- The information patients rely on — clinic consultations, social media, online forums — rarely presents balanced evidence, leaving them to make high-stakes decisions in an epistemic fog.
- A University of Melbourne-launched website providing independent, evidence-based IVF information showed measurable results: patients who used it better understood the evidence and were less likely to pursue unsupported add-ons.
- Researchers are now calling for structural reform — requiring clinics to direct patients to independent resources — but whether the fertility industry will accept such accountability remains an open question.
In the quiet desperation of fertility treatment, hope is a powerful currency — and a vulnerable one. A University of Melbourne study has found that most commonly offered IVF add-ons lack meaningful scientific evidence of improving pregnancy outcomes, raising a deeper question about how medicine navigates the space between possibility and proof. When clinics offer unverified treatments to patients already carrying the weight of longing, the line between care and exploitation becomes difficult to see. The challenge now belongs not only to researchers, but to an entire industry asked to choose transparency over profit.
Women pursuing IVF in Australia are routinely offered optional add-ons — extra procedures and medications layered onto standard treatment cycles — with little scientific justification. A University of Melbourne research team reviewed ten of the most commonly marketed options and found that only three showed even weak evidence of possible benefit. The remaining seven demonstrated no meaningful effect on pregnancy success, or produced results too limited to be conclusive. The findings were published in The Lancet Obstetrics, Gynecology and Women's Health.
The add-ons reviewed ranged from preimplantation genetic testing and endometrial receptivity testing to acupuncture, platelet-rich plasma injections, and intralipids. Only EmbryoGlue, endometrial scratching, and physiological intracytoplasmic sperm injection showed any weak signal of benefit. Lead researcher Dr. Sarah Lensen noted that the problem extends beyond individual clinical choices — when clinics offer these treatments, patients naturally read their availability as endorsement.
The information environment makes things worse. Patients typically learn about add-ons through clinic staff, social media, and online forums, none of which reliably present the full evidentiary picture. This leaves people making consequential decisions about their bodies and finances without access to clear, independent guidance.
In April 2025, the University of Melbourne launched the Evidence-based IVF website to address this gap. A large trial found it improved patient understanding of benefits and risks, and meaningfully reduced interest in add-ons lacking strong support — demonstrating that honest information, when accessible, genuinely changes behavior. Lensen has proposed requiring clinics to direct patients toward such independent resources, shifting the foundation of fertility decisions from marketing to informed consent. Whether the industry will move in that direction remains to be seen.
Women in Australia pursuing in vitro fertilization are regularly offered optional add-ons—extra procedures, medications, or techniques layered onto standard IVF cycles—with little scientific backing that they work. A University of Melbourne research team examined ten of the most commonly marketed add-ons by analyzing data from clinical trials. What they found was sobering: only three showed even weak evidence of benefit. The other seven had either no demonstrated effect on pregnancy success or results too limited or poor-quality to draw conclusions from.
The add-ons under review included preimplantation genetic testing for aneuploidy, endometrial receptivity testing, corticosteroids, EmbryoGlue, endometrial scratching, physiological intracytoplasmic sperm injection, platelet-rich plasma injection into the ovary, platelet-rich plasma infusion into the uterus, acupuncture, and intralipids. Of these, only EmbryoGlue, endometrial scratching, and physiological intracytoplasmic sperm injection showed any weak evidence of possible benefit. The findings, published in The Lancet Obstetrics, Gynecology and Women's Health, arrive at a moment when fertility clinics have increasingly expanded their menus of optional treatments over the past decade.
Dr. Sarah Lensen, lead author and researcher in the University's Department of Obstetrics, Gynecology and Newborn Health, framed the stakes plainly: unproven add-ons create false hope, deepen financial strain, and expose patients to unnecessary medical procedures at a time already marked by emotional difficulty. The problem runs deeper than individual clinical decisions. When clinics offer these treatments, patients often interpret their availability as implicit endorsement—a signal that they work. The result is that many women undergoing IVF opt for one or more of these extras, despite the absence of solid evidence supporting them.
The information landscape compounds the problem. Patients learn about add-ons through clinic recommendations, social media, and online forums—sources that rarely present the full evidentiary picture or acknowledge what remains unknown. This fragmented information environment leaves people trying to make consequential decisions about their bodies and finances without access to clear, balanced, evidence-based guidance. Lensen emphasized that navigating the claimed benefits and potential harms of fertility treatments is genuinely confusing under these conditions.
In response to this gap, the University of Melbourne launched the Evidence-based IVF website in April 2025, designed to provide patients with independent, accessible information about common add-ons. When the team tested the site in a large trial, the results were encouraging: it improved patients' understanding of benefits, risks, and the quality of underlying evidence. More significantly, it reduced interest in add-ons lacking strong scientific support—suggesting that clear information, when available, actually shapes patient choices.
Lensen proposed a structural solution: clinics could be required to direct patients toward independent, evidence-based resources rather than relying on clinic-provided information alone. Such a requirement would help ensure that decisions about fertility treatment rest on informed consent rather than on what patients happen to encounter online or what they're told in a clinic consultation. The challenge now is whether the fertility industry will embrace stronger safeguards around information, or whether the current landscape—where unproven treatments remain widely available and marketed—will persist.
Bemerkenswerte Zitate
Unproven add-ons can lead to false hope, greater financial strain and unnecessary medical procedures at what already can be a very difficult time for patients.— Dr. Sarah Lensen, University of Melbourne
Clinics could be required to direct patients to independent, evidence-based resources to help ensure patients are making informed decisions, not just relying on what they're told or what they find online.— Dr. Sarah Lensen
Möchten Sie die ganze Geschichte?
Das Original lesen bei Medical Xpress ↗
Science & Space